Well-established efficacy of camrelizumab combined with radiofrequency ablation in cirrhotic patients with hepatic cancer.
In an observational comparison of 89 cirrhotic patients with hepatic cancer, camrelizumab plus radiofrequency ablation was associated with a higher reported response rate and favorable biomarker changes versus ablation alone, without a significant difference in overall adverse-reaction incidence.
Open original publication →What the AI sees
In an observational comparison of 89 cirrhotic patients with hepatic cancer, camrelizumab plus radiofrequency ablation was associated with a higher reported response rate and favorable biomarker changes versus ablation alone, without a significant difference in overall adverse-reaction incidence.
Research significance
The record provides preliminary human evidence that adding camrelizumab to radiofrequency ablation may improve treatment response in cirrhosis-associated hepatic cancer; whether immune modulation causes this benefit, improves durable clinical outcomes, or applies to pediatric patients remains an inference requiring controlled prospective testing.
Source abstract
OBJECTIVE: To analyze the efficacy of camrelizumab combined with radiofrequency ablation (RFA) in cirrhotic patients with hepatic cancer. METHODS: A total of 89 cirrhotic patients with hepatic cancer were enrolled. The control group (n = 40) received RFA alone, and the research group (n = 49) received camrelizumab combined with RFA. Their clinical data were compared, including efficacy, liver function indicators, inflammatory markers, serum tumor markers, humoral immune function parameters, and incidence of adverse reactions. Factors influencing the efficacy and safety of treatment in these patients were also explored. RESULTS: The research group demonstrated a significantly higher total effective rate than the control group (89.80% vs. 70.00%, P = 0.018). Post-treatment, the research group had significantly lower liver function indicators (serum total bilirubin (TBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST)), inflammatory markers (Interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), high-sensitivity c-reactive protein (hs-CRP)), and serum tumor markers (alpha-fetoprotein (AFP), liver cancer paternally expressed gene 10 (PEG10), and carbohydrate antigen 199 (CA199)) (all P<0.05). In contrast, the research group had significantly higher humoral immune function parameters (immunoglobulin A (IgA), IgG, IgM), with statistically significant differences (all P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P = 0.864). Finally, Child-Pugh Class B, tumor size ≥4 cm, AST ≥77 U/L, AFP ≥420 μg/L, and treatment with RFA alone were found to be associated with an increased risk of treatment failure or adverse events (all P<0.05). CONCLUSION: The combination of camrelizumab and RFA demonstrates superior efficacy in the treatment of cirrhotic patients with hepatic cancer.